Topline results released last month from the Phase III ATTAIN-MAINTAIN trial (NCT06584916) found that over 52 weeks, orforglipron achieved the primary endpoint in producing superior percent maintenance of weight loss vs
Interim pharmacokinetic and safety updates continue to support the Phase 2 profile, and researchers are closely watching for the larger, longer-duration data that will ultimately shape the regulatory trajectory for the molecule
Duration: Episodes last a median of 2 days
Yes, adding 1mL creates a 5.0mg/mL concentration
Smirnova GV, Oktyabrsky ON
Protein Pacing: Why Distribution Still Matters While total daily protein intake matters most, how you distribute that protein can matter, especially during weight loss